Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients

Texto completo
Autor(es):
Pedrosa, Tatiana [1] ; Kanda Kupa, Leonard de Vinci [1, 2] ; Pasoto, Sandra Gofinet [1] ; Aikawa, Nadia Emi [1, 3] ; Borba, Eduardo Ferreira [1] ; Duarte, Nilo J. C. [2] ; Leon, Elaine Pires [1] ; Silva, Clovis Artur [3] ; Bonfa, Eloisa [1]
Número total de Autores: 9
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Rheumatol Div, Sao Paulo - Brazil
[2] Univ Sao Paulo, Div Cent Lab, Sao Paulo - Brazil
[3] Univ Sao Paulo, Pediat Rheumatol Unit, Sao Paulo - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Lupus; v. 30, n. 4, p. 554-559, APR 2021.
Citações Web of Science: 0
Resumo

Introduction In 2016 the American Academy of Ophthalmology(2016-AAO) recommended a maximum daily HCQ use of 5.0 mg/kg real body weight(RBW) taking into consideration minimizing eye toxicity. Retinopathy in systemic lupus erythematosus(SLE) patients was recently associated with obesity and this condition is progressively more common in these patients. However, the impact of obesity in HCQ blood levels remains controversial. Objective To determine if the 2016-AAO recommendation based on RBW with and without maximum daily dose restriction results in adequate and safe blood levels in obese lupus nephritis(LN) patients. Methods A cross-sectional study was performed with 108 LN patients under the prescribed 2016-AAO dose for at least 3 months. LN patients were assessed for demographic characteristics, body mass index(BMI), disease parameters, HCQ dose, concomitant treatment and HCQ blood levels measured by liquid chromatography-tandem mass spectrometry. Obesity was defined as BMI >= 30kg/m(2). Results Obesity was identified in 35/108(32%) LN patients. The calculation of HCQ daily dosage revealed that obese patients were under a lower prescribed daily dose according to the real body weight (RBW) {[}4.4(2.9-5.4) vs. 4.9(4-5.5)mg/Kg/day, p < 0.001] due to the maximum limit used. Regardless of that the median of HCQ blood levels was significantly higher in obese compared to non-obese patients (1562 +/- 548.6 vs. 1208 +/- 448.9 ng/mL, p = 0.002). Further analysis of patients under the 20016-AAO recommendation by RBW without the restriction of maximum daily dose confirmed that in spite of comparable daily dose in 14 obese patients and 61 non-obese patients {[}4.8 (4.5-5.4) vs. 5.0(4.5-5.5) mg/kg, p = 0.312], the median of HCQ blood levels was significantly higher in obese patients than in non-obese (1734 +/- 457.3 vs. 1189 +/- 449.4 ng/mL, p < 0.001). Conclusion Obese patients under the 2016-AAO prescribed dose of HCQ based on RBW with and without maximum daily dose restriction have a very high HCQ blood levels compared to non-obese patients, with a potential increased risk of ocular toxicity. The use of 2016-AAO dose of HCQ according to the ideal body weight for this group of patients should be considered.Clinicaltrials.gov \#NCT0312243. (AU)

Processo FAPESP: 19/17272-0 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
Beneficiário:Leonard de Vinci Kanda Kupa
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 15/03756-4 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
Beneficiário:Eloisa Silva Dutra de Oliveira Bonfá
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 17/14352-7 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
Beneficiário:Tatiana Do Nascimento Pedrosa
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 17/03983-6 - Sistema de cromatografia líquida e espectrometria de massa no processo 2015/03756-4
Beneficiário:Eloisa Silva Dutra de Oliveira Bonfá
Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários